According to CymaBay Therapeutics 's latest financial reports the company's current revenue (TTM) is $31.07 M. In 2022 the company made a revenue of N/A a decrease over the years 2021 revenue that were of N/A.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Year | Revenue | Change |
---|---|---|
2023 (TTM) | $31.07 M | |
2022 | N/A | |
2021 | N/A | |
2020 | N/A | |
2019 | N/A | |
2018 | N/A | -100% |
2017 | $10 M | |
2016 | N/A | |
2015 | N/A | |
2014 | N/A | |
2013 | N/A |
Company | Revenue | Revenue differencediff. | Country |
---|---|---|---|
Pfizer PFE | $58.49 B | 188,156.69% | ๐บ๐ธ USA |
Bristol-Myers Squibb BMY | $45.53 B | 146,438.80% | ๐บ๐ธ USA |
Xencor XNCR | $0.16 B | 441.75% | ๐บ๐ธ USA |
PTC Therapeutics
PTCT | $0.93 B | 2,918.13% | ๐บ๐ธ USA |